Skip to content

Functional MRI connectivity guided personalised targeting to optimise rTMS treatment efficacy in neuropathic pain conditions

Personalised targeting to optimise rTMS treatment efficacy in neuropathic pain conditions

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400094568
Enrollment
Unknown
Registered
2024-12-24
Start date
2025-01-15
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic neuropathic pain

Interventions

Experimental group:Received 10 transcranial magnetic stimulation treatments within two weeks

Sponsors

Affiliated Hospital of Hangzhou Normal University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosis of peripheral nerve pathic pain in accordance with IASP, with a course of >=3 months; 2. Or neuropathic pain caused by nociceptive pain (ID PAIN scale>=2 points); 3. 18-75 years old; 4. The average daily pain VAS score in the past 1 week > 30 mm; 5. Can cooperate with clinical evaluation, magnetic resonance scanning and rTMS treatment; 6. No history of pain control medication adjustment within 1 week during the baseline assessment period; 7. Able to understand the nature and purpose of the study, willing to participate and able to comply with the requirements of the study protocol, and willing to cooperate with relevant follow-up.

Exclusion criteria

Exclusion criteria: 1. Contraindications to TMS and magnetic resonance examination (such as magnetic objects and implants or presence of metal pieces or foreign body residues in the body; presence of an acute wound or surgical wound that has not healed; claustrophobia; whether the vessel has any type of stent, clip or surgery; inability to lie on your back due to illness, etc.); 2. Patients with psychiatric illness, aphasia, or cognitive dysfunction (17 HAMDs>24, 14 HAMA>29, MMSE<=24); 3. Those with severe cardiopulmonary dysfunction, extreme weakness, unable to sit upright and cooperate with rehabilitation assessment and treatment; 4. Have other diseases that may interfere with the results of the study, such as epilepsy, myocardial infarction, etc.; 5. Pregnant or lactating women; 6. Is participating in other clinical studies or using other experimental drug treatments.

Design outcomes

Secondary

MeasureTime frame
Neuropathic pain symptom and sign score;Pain interferes with daily activities;Sensory and emotional pain;Patient-rated overall pain improvement;Patient with changes in depression and anxiety;The overall health of the patient;Magnetic resonance functional connection;

Primary

MeasureTime frame
Pain intensity;

Countries

China

Contacts

Public ContactXianwei Che

Affiliated Hospital of Hangzhou Normal University

xwcheswu@gmail.com+86 180 7285 2895

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 25, 2026